This webinar will discuss a study to compare two different liquid biopsy approaches — one based on real-time PCR and one based on mass spectrometry — in patients with advanced lung cancer.

With liquid biopsy entering the routine in personalized cancer treatment it is important to understand the differences inherent to technologies for analyzing circulating tumor DNA (ctDNA) and its implication for the patient.

The study is using both a real-time PCR assay and a MALDI-TOF assay on blood samples taken from patients with advanced lung cancer at time of diagnosis or during follow-up of treatment by EGFR inhibitors.

Initial results demonstrate that the MassArray UltraSeek Lung panel is a sensitive and accurate technology for ctDNA analysis and that this sensitive method could potentially detect more patients with EGFR mutations who could benefit from a targeted therapy — particularly at the time of diagnosis.